Mikael Engskog

Kort presentation

Denna text finns inte på svenska, därför visas den engelska versionen.

I’m a medical doctor (bioanalytical chemistry) now working with metabolomics using both nuclear magnetic resonance and mass spectrometry as detection techniques.

Of particular focus is sample preparation strategies and analytical method development (data quality and reproducibility). I have experience working with plasma and cellular extracts.


Denna text finns inte på svenska, därför visas den engelska versionen.

I have a magisterexam (Biomolecular Chemistry, University collage of Södertörn) with a clear focus on organic chemistry and bioanalytical chemistry. The exam also cover the fields of pharmacology, biochemistry and physical chemistry.

My Ph D. was conducted at Karolinska Institutet, at the unit for analytical carbohydrate chemistry (Prof. Elke Schweda). The thesis deals with the structural characterization of lipopolysaccharides (Haemophilus influenzae) by methods such as masspectrometry, chromatography and NMR. The projects were done in collaboration with a group at Oxford University (Molecular Infectious Diseases Group and Department of Paediatrics). This experience has given me a wide understanding for the field of analytical chemistry when dealing with both practical labwork (sample preparations/purifications (with special focus on carbohydrates) and method development.

Technical skills:

Analytical Chemistry/Organic Chemistry/Analytical Methodlogy
Metabolomics (untargetted, cells and plasma)
NMR (1H, 13C and 31P) 1D/2D
Masspectrometry (GC-MS, ESI-MS, ESI-MSn, HPLC-ESI-MS, CE-ESI-MS/MS)
Chromatography (GC, HPLC and UPLC)
Extraction techniques of lipopolysaccharides
Sample purification
Organic chemistry related modifications of carbohydrates
Basic knowledge molecular biology related techniques (PCR, Western etc)


A dual role for the lex2 locus: identification of galactosyltransferase activity in non-typeable
Haemophilus influenzae strains 1124 and 2019.
Engskog MK, Yildirim HH, Li J, Richards JC, Deadman M, Hood DW, Schweda EK.
Carbohydr Res. 2009 Mar 31;344(5):632-41. Epub 2009 Jan 17.

Lex2B, a phase-variable glycosyltransferase, adds either a glucose or a galactose to
Haemophilus influenzae lipopolysaccharide.
Deadman ME, Hermant P, Engskog M, Makepeace K, Moxon ER, Schweda EK, Hood DW.
Infect Immun. 2009 Jun;77(6):2376-84. Epub 2009 Mar 16.

Genes required for the synthesis of heptose-containing oligosaccharide outer core extensions
in Haemophilus influenzae lipopolysaccharide.
Hood DW, Deadman ME, Engskog MK, Vitiazeva V, Makepeace K, Schweda EK, Moxon R.
Microbiology. 2010 Nov;156(Pt 11):3421-31. Epub 2010 Aug 5.

Detailed structural features of lipopolysaccharide glycoforms in NTHi strain 2019.
Engskog MK, Mary Deadman, Jianjun Li, Derek W. Hood, Elke K. H. Schweda
Carbohydr Res. 2011 Jul 15;346(10):1241-9. Epub 2011 Apr 28.

Nuclear magnetic resonance spectroscopy for analysis of intra-cellular metabolites
Engskog MK, Haglöf J, Elmsjö A, Aftab O, Gustafsson M, Arvidsson T and Pettersson C
In manuscript (expected submission in summer 2012)

Structural analysis of the lipopolysaccharide from invasive non-typeable
Haemophilusinfluenza strain R2866.Engskog MK, Mary Deadman, Jianjun Li, Derek W.
Hood, Elke K. H. Schweda
In manuscript (expected submission in summer 2012)

Acute toxic effects of BMAA in rodents: a metabolomics approach
Elmsjö, A, Engskog MK, Haglöf J, Karlsson O, Brittebo E, Arvidsson T and Pettersson C
In manuscript (expected submission in autumn 2012)


Senaste publikationer

Alla publikationer



Mikael Engskog